ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above Fifty Day Moving Average - Should You Sell?

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $2.41 and traded as high as $3.75. ProQR Therapeutics shares last traded at $3.58, with a volume of 260,707 shares traded.

Wall Street Analysts Forecast Growth

Separately, Raymond James raised ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their price target for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $5.88.

ProQR Therapeutics Trading Up 1.7 %

The business has a fifty day moving average of $2.41 and a 200-day moving average of $2.07. The company has a market cap of $297.32 million, a PE ratio of -12.55 and a beta of 0.26.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.09. The firm had revenue of $6.79 million for the quarter, compared to analysts' expectations of $3.32 million. ProQR Therapeutics had a negative return on equity of 55.42% and a negative net margin of 140.17%. As a group, research analysts predict that ProQR Therapeutics will post -0.31 EPS for the current year.

Hedge Funds Weigh In On ProQR Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Privium Fund Management B.V. grew its position in shares of ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company's stock worth $10,251,000 after buying an additional 51,663 shares during the period. Ikarian Capital LLC boosted its stake in ProQR Therapeutics by 2.3% during the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company's stock worth $1,098,000 after acquiring an additional 10,958 shares in the last quarter. OneDigital Investment Advisors LLC grew its holdings in ProQR Therapeutics by 37.0% in the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 15,550 shares during the period. BNP Paribas Financial Markets increased its stake in shares of ProQR Therapeutics by 120.1% during the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company's stock valued at $80,000 after purchasing an additional 19,100 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in shares of ProQR Therapeutics during the first quarter valued at approximately $56,000. 32.65% of the stock is owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).